Another study reported that punicalagin (12.5 - 200 μM) can affect the viability and proliferation of cervical cancer cells HeLa in a time- and dose-dependent manner by induction of cell cycle arrest in the G1 phase, induction of apoptosis by modulating the expression of apoptosis-associated proteins, downregulating the expression of anti-apoptotic Bcl-2, and upregulating the expression of pro-apoptotic Bax (47). The gene discussed is BCL2; the disease is cervical carcinoma.